Hemogenyx Pharma Stock Price, News & Analysis

Hemogenyx Pharmaceuticals (LSE:HEMO) has successfully raised £570,000 through an allotment of 316,667 new ordinary shares at 180p per share, representing a premium to the market price. The shares were initially subscribed by CEO Vladislav Sandler and will be directed to a small group of investors.

The funding will support the continuation of the company's Phase I clinical trials for HG-CT-1, a Chimeric Antigen Receptor T-cell therapy targeting relapsed/refractory acute myeloid leukemia in adults. The investors will also receive one-for-one warrants exercisable for 36 months at 180p.

Following admission, expected around September 4, 2025, the company's total issued shares will be 5,043,896. The premium-priced fundraising reflects investor confidence in Hemogenyx's progress and long-term prospects.

Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF) has successfully treated the third patient in its Phase I clinical trial of HG-CT-1, a proprietary CAR-T cell therapy for relapsed/refractory acute myeloid leukemia (R/R AML). This marks the completion of the first adult dose cohort, achieved after receiving special FDA permission under exceptional circumstances.

The company reported encouraging early results, with the first two patients remaining alive at six and three months post-treatment. Following this milestone, Hemogenyx plans to advance to a second adult dose cohort with twice the initial dose and initiate a pediatric trial arm. The Phase I trial aims to evaluate safety and secondary endpoints including anti-leukemic activity, survival rates, and duration of response.

Hemogenyx Pharmaceuticals (OTC:HOPHF) has secured £250,000 through a strategic share placement, issuing 133,690 new ordinary shares at 187p per share, representing a premium to the current market price. The shares will be initially allotted to CEO Vladislav Sandler, who will then transfer them to a group of new investors.

The funding will support the continuation of the company's Phase I clinical trials for HG-CT-1, their Chimeric Antigen Receptor T-cell therapy targeting relapsed/refractory acute myeloid leukemia in adults. The company reports that the first two patients have completed four-week safety trials with encouraging early efficacy signs.

The deal includes one-for-one warrants exercisable at 187p for 36 months. Upon admission of the new shares, expected around August 7, 2025, the total number of issued shares will be 4,727,229.

Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF) has secured a $120,000 G-Rex® grant from ScaleReady, in partnership with Wilson Wolf Manufacturing and Cell Ready. The grant will support the optimization and scale-up of manufacturing for HG-CT-1, the company's lead CAR-T product candidate currently in Phase I trials for relapsed/refractory acute myeloid leukemia.

The funding will enable development of a closed-system, G-Rex®-based manufacturing platform, aimed at reducing production complexity, enhancing regulatory compliance, and lowering per-patient manufacturing costs. The grant includes technical consulting support in lean bioprocessing, regulatory strategy, and process engineering to support future clinical and commercial-scale manufacturing.

Hemogenyx Pharmaceuticals (HOPHF) has received FDA clearance to expand its Phase I clinical trial of HG-CT-1, a proprietary CAR-T therapy for relapsed/refractory acute myeloid leukemia (R/R AML), to include pediatric and adolescent patients. The FDA's 30-day review period concluded without a clinical hold, allowing the company to proceed with Institutional Review Board submissions and site activation procedures for pediatric cohorts. This expansion broadens the potential therapeutic reach of HG-CT-1 and represents a significant milestone in the company's development program, particularly in addressing the needs of younger patients with this aggressive form of leukemia.

Hemogenyx Pharmaceuticals has raised £451,250 through a placing of 250,000 new ordinary shares at 180.5p per share to CEO Vladislav Sandler, who will direct their issue to an institution for immediate sale to a purchaser. The purchaser will receive one-for-one warrants exercisable for 36 months at 270 pence. The funding will support the continuation of Phase I clinical trials for HG-CT-1, the company's CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia in adults. Two patients have already been infused with HG-CT-1. Upon admission of the new shares, expected around June 13, the total number of issued shares will be 4,593,539. The placement was completed at a premium to market price, demonstrating investor confidence in Hemogenyx's long-term potential.

Hemogenyx Pharmaceuticals (HOPHF) has announced successful safety evaluation of the second patient treated with HG-CT-1, their proprietary CAR-T therapy for relapsed/refractory acute myeloid leukemia (R/R AML) in adults. The Phase I dose-escalation trial showed favorable safety profile and early efficacy signs. The study includes secondary endpoints evaluating overall survival, progression-free survival, and response duration. Manufacturing for a third patient's treatment is underway. CEO Dr. Vladislav Sandler emphasized the significance of this milestone in addressing aggressive leukemia treatment, highlighting the therapy's potential for patients with limited options.

Hemogenyx Pharmaceuticals (LSE:HEMO) has filed an amendment to its ongoing Phase I clinical trial protocol for HG-CT-1, its CAR-T therapy for relapsed/refractory acute myeloid leukemia (R/R AML). The amendment seeks to expand trial eligibility to include children and adolescents, beyond the current adult patient population. This expansion aims to address a critical unmet medical need in pediatric oncology, particularly for R/R AML, which has limited treatment options and poor prognosis. The company has already treated two patients in the adult cohort of the trial.

Hemogenyx Pharmaceuticals (LSE:HEMO) has successfully raised £451,250 through a placing of 250,000 new ordinary shares at 180.5p per share. The shares were initially allotted to CEO Vladislav Sandler, who will direct their issue to an institution for immediate sale to an identified purchaser. The purchaser will receive one-for-one warrants exercisable for 36 months at 270 pence.

The funds will support the continuation of Phase I clinical trials for the company's HG-CT-1 therapy, targeting relapsed/refractory acute myeloid leukemia in adults. Two patients have already been infused with the treatment. Upon admission of the new shares, expected around May 14, 2025, the total number of issued shares will be 4,343,539.